Issue: March 2012
September 28, 2011
1 min read
Save

Santen acquires controlling interest in Novagali

Issue: March 2012
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

OSAKA, Japan — Santen Pharmaceutical has come to an agreement with Novagali Pharma and key shareholders that will grant Santen 50.55% control of Novagali.

Santen purchased the shares at a price more than 71% above Novagali's closing share price Sept. 27. It intends to purchase all remaining shares at the same price and then file a mandatory tender offer.

"Santen believes that by acquiring Novagali, it will be able to strengthen its global business platform," Akira Kurokawa, Santen CEO and president, said in a press release. "Our corporate values are committing Santen to contribute to the protection and improvement of people's eyesight and health as a specialty company in the ophthalmic and anti-rheumatic fields."

"We strongly believe that Santen represents a perfect strategic fit for Novagali Pharma to expand the commercial success of Cationorm and bring Cyclokat to patients," Jerome Martinez, CEO of Novagali, said in the release.

A share purchase agreement has been approved by Santen's board of directors and Novagali's supervisory board and management board.